Kazia Therapeutics Limited (KZIA)
| Market Cap | 84.00M |
| Revenue (ttm) | 731,724 |
| Net Income (ttm) | -8.60M |
| Shares Out | 62.17M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $10.28 |
| Previous Close | $10.49 |
| Change ($) | -0.21 |
| Change (%) | -2.00% |
| Day's Open | 10.76 |
| Day's Range | 10.20 - 10.74 |
| Day's Volume | 100,601 |
| 52-Week Range | 2.56 - 13.47 |
News
Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.
About KZIA
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St ... [Read more...]
| Industry Biotechnology | IPO Date Jan 6, 1999 |
| CEO Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( | |
| Stock Exchange NASDAQ | Ticker Symbol KZIA |
Financial Performance
In 2020, KZIA's revenue was 1.06 million, a decrease of -32.20% compared to the previous year's 1.57 million. Losses were -12.47 million, 21.4% more than in 2019.
Analyst Forecasts
According to one analyst, the rating for KZIA stock is "Buy" and the 12-month stock price forecast is 17.03.